and to the cancer good At Thank you, epigenetic treatment of vision and is medicines. everyone. Jason, novel our rewrite other Epizyme, development serious morning, through of the diseases
bring patients will in to cancers. ultimate a of improvements combinations. We Epizyme’s to and first-in-class malignancies We are their treat tazemetostat’s hematological believe of inhibitor oral EZHX a that to patients is tumors, our in pioneers treatment being a strongly tazemetostat, of with monotherapy in this meaningful lives. potential for and treatment field, with leading in as make the investigational evaluated the goal both range medicines way solid
portfolio We the for have and a financial and our set our discipline focus near longer-term. both strategic priorities that driving of are clear
we in utilizing a believe, lead The multiple accelerated advancing sarcoma development our opportunities, lymphoma, follicular these approval the to us. monotherapy first priorities is and as tazemetostat epithelioid are available two of indications;
We and sarcoma, and submission first for on FL, in for milestone trial. initiating tazemetostat our are path for And monotherapy focused combo our a in epithelioid preparing registration our are NDA organization. defining a major we
for Our additional its second maximize and potential. therapeutic indications priority to to strategic tazemetostat combinations identify is
advance in we it. based be to in on tazemetostat, learn our the with tazemetostat and potential development and we the a scientific combinations different data, of As rationale of about we number cancers. care targeted And standards more agents both clinical other of holds believe used
this Agarwal Chief new Dr. in Medical a role Officer Our critical front. Shefali will play
Under our to call morning. her a and by management the late-stage nearly FDA pleased for is we are of with recent engagement, strong tazemetostat’s build out strong us the to experienced years clinical round next record joining Agarwal. track the and she Epizyme, the tazemetostat this further team Dr. of of leadership, We highly very development oncology explore. and significant value brings to indications upon with of potential defining combinations experience appointment to set XX and She intend pipeline and expertise product
advance on to than other today’s EZMXXXX clinical partial toward. cell note In Epizyme won’t diligently in and working We at disease. GXa they this our portfolio. regulatory with to our in our is is to strategic Our tazemetostat the we authorities options on significant trials, working that clinical the on call have everyone hold which however, single focus our the novel in priority most short-term, objective third resolve represent pipeline stage is others meaningful inhibitor, early compound sickle
me let start there. So,
solid of the in was enrollment I U.S., due safety one our regarding paused As enrolled that ranging This pediatric, to in being in tazemetostat Germany. a the we and reminder, a authorities second portion by in patient informed France quarter, was report tazemetostat tumor for this patients Phase This regulatory a on prognosis, and and secondary trials The were the achieved patient an new had our dose metastatic months T-lymphoblastic differentiate of chordoma following was case to objective therapy. poor study of T-LBL. XX entered developed monotherapy. response who or study child poorly with several the lymphoma prior rounds
treatment T-LBL diagnosis, quite is the and told, began a the discontinued tazemetostat Following patient lymphoma. are the this patient And type of standard responding for we well.
to in completed address patients. several to to trials. enrollment with key hold our steps reopen include our We the investigators clinical partial re-consent working These have all
have opted report. supportive safety who and any has very we’re patient been not aware due discontinue investigators the Our to to of treatment
understand and of available have literature better finalized of detailed we T-LBL. to clinical case data the this Additionally, evaluation
We of trials patient in also pediatric clinical with assessment and both proactively to-date across data safety activity populations. undertook and comprehensive and the tazemetostat recently clinical adult completed observed a
that We study validate populations and panel patient assessments. any this are regulatory have for which in our consulted changes of and convened include external experts response review malignancies to may trials potential protocols, secondary potential handled. these to to changes with be to proposed treatment and a that in could plan to We may information we and it future how our inform investigating utilize to include authorities be the
ahead the our those to that that will to in to authorities. the have in Germany, further to us regulators define finalize to proceed. U.S., and gain regulatory be and plan process work engage lifted able scientific hold with that response with enrollment the anticipate in position we we FDA Now France, the enable Once additional clinical complete, partial the is to our weeks countries be would alignment the gained we insight will
lymphoma tazemetostat lymphoma B-cell potential about gained about Now, let in tazemetostat’s we our me we’ve for diffuse optimistic why large follicular review or learnings DLBCL. prospects and the in are
June, tazemetostat’s FL of a cohorts in EHA FL patients activity presented been cohorts. EZHX. investigating EZHX multi-cohort Phase we conducting are with As interim with or evaluating Two in trial data these recall, a you positive study II large both in this in may wild-type tazemetostat FL DLBCL. we’ve monotherapy mutations refractory as patients relapsed patients with At and and from
XX FL date patients In XX% still tumor had therapy to who the cutoff, as volume these well in and weeks, of EZHX, meaningful. resulted but, these the in mutations. led tumor stood of objective reduction is and on X least the only adverse stable many events the least being treatment were on XX% patients an patients duration cohort we response Both achieved achieving tazemetostat a at been cohort. monotherapy an adverse of as in objective more that disease tazemetostat the of with the majority believe to believe figures were at of the of patients, rate was a patients than was median X achieve these responders this the An survival new Congress heavily wild-type this response, activating this X in at response. objective on continue or withdrawals. in May higher treatment impressive patients some cutoff an FL Notably, response therapy as rate in response. added of volume in substantial of for tazemetostat continues out The therapy. still resulted population. of with remaining best for EZHX a to response reduction is This patients. generally to of to XX some XX% response, evaluable Grade median were with the of the We responding all Only of event, ORR with best opportunity As were of which of May be which patients of progression-free XX% X% additional tolerated with as very patients a treatment-related discontinuations majority benefit what to is patients mature was treatment-emergent mature, weeks. durability Tazemetostat date with we pre-treated and or XX-week as in with XX%, pleased also duration experienced
in pretreated by We The FL strong. with activating responses with continue of these with response path clinical we resolved heavily treatment and in remained for the maturing. of refractory EZHX seen mutations rate the still been the to patients to be define durations registration patients Meaningful have we are to relapsed these re-engage have EZHX the patients FDA data. Once partial FL. excited wild-type response hold, plan in
DLBCL etiology progression. all in DLBCL may and lines more treatment upon aggressive is almost know, approaches are and their combination both the considerations different of is diseases, As the terms in disease and always therapy very with of FL therapy. you treated
as addition, wild-type EZHX. enrolled Phase a refractory patients the In tazemetostat we highly in monotherapy in we’ve patients mutations pretreated In have patients our are and and DLBCL treatments. EZHX study with with to investigating II been trial, previous heavily our their
these of active tazemetostat on observed patients. study wild-type prednisolone, well additional also our We that that in and a combination II is Phase generally in in is with in cohort evaluating clinically trial Based have we cohorts, DLBCL EZHX. the interim with tolerated tazemetostat the recent assessment steroid an patients have DLBCL three
the consideration in that and activity into from needed monotherapy a be to other clinical taking a to after input level landscape, along decided DLBCL We pursue cohorts and combination findings we plan we XXXX. the DLBCL. will half prednisolone enrolling cohorts tazemetostat treatment evolving able of II clinical Patients medical path the However, the have DLBCL are than investigators be with would our therapy. in trial. additional not with a ongoing advance meeting in responses to of cohorts not patients these to remain on in these at in from But Phase second report these
know difficult. that one are inherently the treatments same indication, in are effect we decisions While have to like going not this every
to science more combinations data. and tumor combination but DLBCL be We already that patient-focused have such ongoing are ultimately, two organization, We a studies believe the to in treating guided other longer-term. We and evaluate plan combinations by we this the aggressive other may in tazemetostat type. effective be need
primary our evaluating DLBCL this for tolerability strategically R-CHOP R-CHOP may for believe be backbone ongoing many we serving frontline with regimen Since a of high-risk cancers, serves Ib patients, as as in The for tazemetostat as first is prove therapy important Epizyme. endpoint safety assessment for combination the trial. a treatment to safety Phase this studies with and
PK And meeting Study study. of the in a we portion Phase or present to LYSA, of to to partner, engage plan of to further the safety, and the the assess them expects II Association the with data advancing the at XXXX. Our half potential second Lymphoma tolerability medical
also has endpoint, Data in combination DLBCL. XXXX. a secondary is combination the we refractory underway The with of is serving tazemetostat efficacy atezolizumab, study primary study pharmacokinetics Phase other trial endpoints. Genentech’s in as with the This safety Ib have from this that or checkpoint expected along and are inhibitor, relapsed investigating
Let’s now conclude opportunity. with our nearest term registration
survival months the to Our for epithelioid of broadly are ES with X patients loss most metastatic, NDA ES. There tissue sarcoma. once these rare, soft submission ES are therapies, been there with approved of currently ages therapies; the characterized first sarcomas, tissue INIX. estimated becomes diagnosed be indicated is is XX disease no that the soft have while commonly are sarcoma. of is Patients utility feedback physician in and aggressive, treatment by It a they limited for only protein planned tazemetostat XX, agents the ES. specifically approved XX and months. for suggests to And for have between
a the quite treatments ES for new As remain need result, high.
In in path have in has who the with ES initial been monotherapy that indicated objective patients for granted patients, our or seen based XX from patients. cohort that of fact, data a interim approval the XX in resulted the II anthracycline-based cohort fully the with a identified consistent assessment trial XX a has ES data tazemetostat same an what the designation has An rate on reviewed which showed full fast-track the the of enrolled. FDA objective response in trial from FDA We from tazemetostat the regimen. data these in cohort we patients. presented ES following been accelerated XX% progressed In the for data and rate in XXXX, on full treatment from Phase treatment remained has response patients first submission of was
for data Medical In data for submission. abstract the recently was continue ESMO will at updated An mature, accepted which our support Oncology addition, just European Congress the to XXXX. our or further presentation NDA with durability Society we believe
data of updated are So, more our fully benefit to to more believe data look XXXX. us will the in strength From October. include durability We the our to clinical submit sharing patients timeline standpoint, we for these are enable matured half and now ES revised demonstrate NDA regulatory we first submission these package of this in forward planning in a receiving. the
in important helping it submission which efforts, is Epizyme, sufficient of we resolve pursue incredibly submission. a us particularly ever in request and We partial also subsequent to team’s will to tazemetostat’s the our lymphoma. pre believe submission robust closer participate clinical potential and hold, patients in provide follicular intend the to Preparing a realizing to I NDA in complete time as meeting, need. am proud bring our
are set we clear we the to on important and a financial As objectives have fully you’ve that to ensure strength heard, focused of strategic accomplish it’s them.
So Susan let to call elaborate. to the over now turn me Susan?
